43Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Croatia
Neuroscience Intelligence
Croatia neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #50 of 50 · Data maturity A · Research score 25.9 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
8Recruiting trials
6Publications
11Institutions
Executive interpretation
Croatia ranks #50 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Boehringer Ingelheim40 recruiting
Hoffmann-La Roche30 recruiting
TauRx Therapeutics Ltd20 recruiting
Genzyme, a Sanofi Company20 recruiting
Bristol-Myers Squibb22 recruiting
Celgene20 recruiting
Eisai Limited20 recruiting
Novo Nordisk A/S20 recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.20 recruiting
Xenon Pharmaceuticals Inc.21 recruiting
Disease activity
Alzheimers10trials
Epilepsy9trials
Multiple Sclerosis6trials
Schizophrenia3trials
Parkinsons2trials
Stroke2trials
Neuromuscular1trials
Other Neurology1trials
Other Psychiatry1trials
Pain Neuropathy1trials
Research institutions
University Hospital for Infectious Diseases "Dr Fran Mihaljevic"OpenAlexlinked institution
Institute for Anthropological ResearchOpenAlexlinked institution
University Hospital Centre ZagrebOpenAlexlinked institution
Andrija Stampar Teaching Institute of Public HealthOpenAlexlinked institution
Gen-infoOpenAlexlinked institution
University of ZagrebOpenAlexlinked institution
Ericsson (Croatia)OpenAlexlinked institution
University of RijekaOpenAlexlinked institution
University of SplitOpenAlexlinked institution
Sisters of Charity HospitalOpenAlexlinked institution
Clinical evidence trail
NCT07544498XR2ESILIENCE - XR-Based Resilience Training for Stress and Mental Health in Healthcare WorkersNOT_YET_RECRUITING
NCT07384845The Role of Transcutaneous Vagus Nerve Stimulation in Treatment of Acute Brain InjuryNOT_YET_RECRUITING
NCT07067463A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisRECRUITING
NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RECRUITING
NCT06976216A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseRECRUITING
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RECRUITING
NCT05667142A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresRECRUITING
NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)ACTIVE_NOT_RECRUITING
NCT05695950A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With DermatomyositisCOMPLETED
Research evidence trail
PUBMEDSteroid-modified lymphoma and the Marburg variant of multiple sclerosis: tissue, time and treatment response. Reply to Hanazono et al.2026-10-16
PUBMEDTwo dopaminergic systems, one bladder: recognising a therapy-resistant urinary phenotype in Parkinson's disease.2026-10-01
PUBMEDSensory Abnormalities and Pain in the Donor Sites of Radial Forearm and Fibula Free Flaps-A Systematic Review.2026-08-18
PUBMEDDeprescribing and Anti-CGRP preventive therapy in medication-overuse headache associated with migraine: pathophysiological rationale and single-center real world evidence.2026-01-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.